Kyle Flanigan, founder of US Specialty Formulations, the maker of QYNDR, said the QYNDR vaccine is called Kinder, because it is an easy way to deliver the vaccine. In addition, the report states that promising clinical trial results from New Zealand raise hopes that qYNDR will be a viable option to protect against the now circulating COVID-19 variant.
Surviving a vaccine through your digestive tract is really challenging, Flannigan said. We were able to figure out how to deliver the vaccine to the stomach and intestine and have it be effective and generate the proper response.
The report said that while scientists expect that mucosal vaccines will not only protect against severe disease and death, mRNA vaccines and boosters also ward off infection. Unlike traditional vaccines, mucosal vaccines enter through our mucous membranes, either through our nose (as in the well-known nasal COVID-19 vaccine) or through our gut (orally in QYNDR).
The report mentions that mucosal vaccines have been supported as a viable or even better option to deal with COVID-19 infection due to different types of immunity and the fact that it starts from where the virus enters our body. enters.